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BACKGROUND. The optimal immunosuppressive regimen in kidney transplant recipients, deliveringmaximum efficacywithminimal
toxicity, is unknown.METHODS. The Amsterdam, LEiden, GROningen trial is a randomized, multicenter, investigator-driven, noninfe-
riority, open-label trial in 305 kidney transplant recipients, inwhich 2 immunosuppressionminimization strategies—one consisting of early
steroid withdrawal, the other of tacrolimus minimization 6 months after transplantation—were compared with standard immunosup-
pression with basiliximab, corticosteroids, tacrolimus, and mycophenolic acid. The primary endpoint was kidney function. Secondary
endpoints included death, primary nonfunction, graft failure, rejection, discontinuation of study medication, and a combined endpoint
of treatment failure. An interim analysis was scheduled at 6months, that is, just before tacrolimusminimization.RESULTS.This interim
analysis revealed no significant differences in Modification of Diet in Renal Disease between the early steroid withdrawal group and the
standard immunosuppression groups (43.2mL/min per 1.73m2 vs 45.0mL/min per 1.73m2,P=0.408). Therewere also no significant
differences in the secondary endpoints of death (1.0% vs 1.5%; P = 0.737), primary nonfunction (4.1% vs 1.5%, P = 0.159), graft failure
(3.1% vs 1.5%, P = 0.370), rejection (18.6% vs 13.6%, P = 0.289), and discontinuation of study medication (19.6% vs 12.6%,
P = 0.348). Treatment failure, defined as a composite endpoint of these individual secondary endpoints, wasmore common in the early
steroid withdrawal group (P = 0.027), but this group had fewer serious adverse events and a more favorable cardiovascular risk profile.
CONCLUSIONS. Based on these interim results, early steroid withdrawal is a safe short-term immunosuppressive strategy. Long-
term outcomes, including a comparison with tacrolimus minimization after 6 months, will be reported in the final 2-year analysis.
(Transplantation Direct 2018;4:e354; doi: 10.1097/TXD.0000000000000794. Published online 15 May, 2018.)Immunosuppression with basiliximab, prednisolone, cal-cineurin inhibitors, and mycophenolic acid results in low
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was designed to compare 2 immunosuppression minimization
strategies—early steroid withdrawal and tacrolimus minimi-
zation after 6 months—to standard immunosuppression
with basiliximab, corticosteroids, tacrolimus, and mycophe-
nolic acid. The aim of the study is to assess whether early ste-
roid withdrawal or tacrolimus minimization can provide
equivalent outcomes in terms of kidney function while limit-
ing immunosuppressive toxicity. In this interim analysis, the
6-month results of early steroid withdrawal are compared
to those of standard immunosuppression. The final analysis
will report the 2-year outcomes and will also include the re-
sults of the tacrolimus minimization group.
MATERIALS AND METHODS
Study design
We conducted a prospective, open label, multicenter, ran-
domized, investigator-driven trial comparing standard im-
munosuppression (basiliximab/corticosteroids/tacrolimus/
mycophenolic acid) to early steroid withdrawal and to tacro-
limus minimization after 6 months.
In this trial, kidney transplant recipients from 3 participat-
ing Dutch academic medical centers were included: the Aca-
demic Medical Center in Amsterdam, Leiden University
Medical Center, and the University Medical Center Gro-
ningen. Approval from the Institutional Review Board of
the participating institutions was obtained, and the trial
was conducted in compliance with the principles of Good
Clinical Practice, the Declaration of Helsinki, and national
laws and regulations. All patients provided written informed
consent and could withdraw from the study at any time.
Patients between the ages of 18 and 80 years who were
scheduled to receive a first or second kidney transplant from
a living donor, donation after brain death (DBD) donor, or
donation after cardiac death (DCD) donor were eligible to
participate in this trial. Patients receiving a kidney from an
HLA-identical related donor were excluded, as were patients
who had more than 75% current or historic panel reactive
antibodies, patients with diabetes mellitus type I, and femaleFIGURE 1. Schematic overview of the study.patients who were unwilling to use adequate contraception
during the study.
Before undergoing kidney transplantation, patients were
randomly assigned in a 1:1:1 ratio to 3 treatment groups
(groups 1, 2a, and 2b) by means of a centralized, interactive
voice-response system. Randomization did not take into ac-
count any specific patient or donor organ characteristic, such
as organ type. All groups received induction therapy with
basiliximab and methylprednisolone. Group 1, the early steroid
withdrawal group, receivednoprednisolonemaintenance immu-
nosuppression. Groups 2a and group 2b both received standard
prednisolone, tacrolimus, and mycophenolic acid for the first
6 months. After 6 months, group 2b was switched to a low-
dose tacrolimus regimen for the remainder of the study. The to-
tal study duration was set at 2 years, with a prespecified interim
analysis scheduled 6 months after the last patient had been in-
cluded. Figure 1 provides a schematic overview of the study.
Detailed Study Medication
All groups received induction treatment with basiliximab
(Simulect, 20 mg intravenously on day 0 and day 4) and
methylprednisolone (500mg, 250mg, 125mg intravenously
on days 0, 1, and 2). Mycophenolic acid (MyFortic) was pre-
scribed at 720 mg twice daily for the first 2 weeks and then
tapered to 540 mg twice daily for the remainder of the study.
Group 1 received no maintenance prednisolone, whereas
prednisolone in groups 2a and 2b was dosed at 10 mg once
daily for the first 6 weeks and then lowered to 7.5 mg once
daily for the remainder of the study.
All subjectsweregiven extended-release tacrolimus (Advagraf),
with a trough level target of 8 to 12 ng/mL for the first 6 weeks,
whichwas then lowered to6to10ng/mL.Forgroup1and2a, this
target trough levelwas continued for the remainder of the study,
whereas in group 2b (the tacrolimus minimization group), tar-
get trough levels were lowered to 3 to 5 ng/mL after 6 months.
Patients with evidence of either donor or recipient cytomeg-
alovirus seropositivity received 6 months of valgancyclovir
(Valcyte) prophylaxis. In addition, all patients were prescribed
6months of Pneumocystis jirovecii prophylaxis (trimethoprim/
sulfamethoxazole or Cotrimoxazole).
© 2018 Wolters Kluwer van Sandwijk et al. 3Safety
All adverse events were monitored and recorded. A data
safety monitoring board was formed, which met after 75
and 150 patients had been included to judge the rate of rejec-
tions and serious adverse events (SAEs). The data safety
monitoring board had the right to terminate the study if
the rejection rate was higher than 30%.
Rejection
Indication biopsies were performed at the discretion of the
treating physician. Rejections were treated identically in both
groups, according to local practice. Patients in the early ste-
roid withdrawal group with a documented rejection were
switched to standard maintenance immunosuppression. Pro-
tocol biopsies in both groupswere performed at 1 and 2 years
after kidney transplantation and are therefore not included in
this 6-month interim analysis.
Efficacy
The primary endpoint of this study was kidney function,
measured as estimated glomerular filtration rate (eGFR) by
means of theModification of Diet in Renal Disease (MDRD)
equation. In addition, creatinine clearance and proteinuria
were obtained from 24-hour urine collections.
Secondary endpoints for the interim analysis consisted of
graft and patient survival, documented rejection episodes, in-
terruption of study medication for more than 6 weeks, SAEs
and cardiovascular risk factors (blood pressure, lipid profile,
and diabetes). In addition, a composite endpoint reflecting
treatment failure was defined as death, primary nonfunction,
graft failure (ie, death-censored graft loss), a documented rejec-
tion, or interruptionof studymedication formore than6weeks.
If patients experienced multiple events, only their first event
was included in the composite endpoint of treatment failure.
Statistical Methods
The sample size was calculated assuming 80% power to
detect noninferiority in terms of eGFR at a significanceFIGURE 2. Enrollment and outcomes.level of 5%. Noninferiority was defined as a difference of
10 mL/min per 1.73 m2 or less in mean eGFR. The standard
deviation of eGFR was estimated at 25 mL/min per 1.73 m2.
This implies a group size of at least 75 patients for each of the
3 groups included in the final analysis. Analyses were per-
formed both on an intention-to-treat and as-treated basis.
For the interim analysis, Student t tests (for MDRD and
creatinine clearance) andMann-WhitneyU tests (for protein-
uria) were used depending on the characteristics of the under-
lying distribution. In case of graft failure, an eGFR of 10 mL/
min per 1.73 m2 and a creatinine clearance of 10 mL/min
were imputed. Sensitivity analyses were run both with and
without imputations for graft failure. Secondary endpoints
were compared by Kaplan-Meier analyses (for death, pri-
mary nonfunction, graft failure, rejection, interruption of
study medication and the composite endpoint of treatment
failure),χ2 tests (for SAEs), and analysis of covariance analyses
(for cardiovascular risk factors).
RESULTS
Patients
From June 27, 2011, to August 6, 2014, 305 patients
underwent randomization (Figure 2). Eight patients had an
inclusion/exclusion violation, so that 297 patients could be
included in the intention-to-treat analysis. After 6 months,
53 of 98 patients had completed the assigned treatment in
the early steroid withdrawal group, compared with 133 of
199 patients in the standard immunosuppression group.
The baseline characteristics of patients in the early steroid
withdrawal and standard immunosuppression group are de-
scribed in Table 1. It shows that both groups were well bal-
anced in terms of demographic characteristics, underlying
renal disease, previous renal replacement therapy, comorbid-
ity, and donor and surgical characteristics.
Tacrolimus trough levels were within predefined bound-
aries and were identical for all groups, with the exception
of week 2 trough levels, which were slightly but significantly
TABLE 1.
Baseline characteristics
Early steroid withdrawal (98 patients) Standard immunosuppression (199 patients) P
Demographic characteristics
Age, y 54.8 ± 14.6 57.5 ± 12.6 0.098
Sex (% male) 68.4% 67.6% 0.905
Race 0.737
White 82.7% 81.3%
Asian 3.1% 5.1%
Black 3.1% 4.5%
Other 11.2% 9.1%
Blood pressure, mm Hg 141/84 141/81 0.877/0.101
BMI 26.5 26.7 0.558
Renal disease characteristics
Primary diagnosis 0.765
Diabetes mellitus type 2 8.2% 9.1%
Hypertension 2.7% 22.2%
Glomerulonephritis 8.2% 14.6%
ADPKD 20.6% 17.7%
FSGS 2.1% 2.5%
Other 38.1% 33.8%
Preemptive transplantation 27.6% 22.7% 0.389
Dialysis modality 0.784
Hemodialysis 36.7% 42.9%
Peritoneal dialysis 20.4% 20.2%
Both 15.3% 14.1%
Prior renal transplantation 4.1% 5.1% 0.725
Renal risk factors
Hypertension 82.5% 77.3% 0.303
Hypercholesterolemia 23.7% 24.2% 0.920
Diabetes 14.4% 19.7% 0.169
Smoking 0.732
None 51.0% 50.5%
Past/current 49.0% 49.5%
Pack-years 14 [8.2-26.9] 16.0 [7.5-36.1] 0.586
CMV status (% IgG positive) 54.1% 56.1% 0.845
EBV status (% IgG positive) 75.5% 82.3% 0.368
Donor and surgical characteristics
Age of donor, y 54.0 ± 14.5 54.9 ± 13.3 0.585
Sex of donor (% male) 46.4% 53.5% 0.249
First or second kidney transplant (%) 0.720
First 95.9% 94.9%
Second 4.1% 5.1%
Postmortal donor 64.3% 55.1% 0.135
DBD 25.5% 19.4% 0.555
DCD 38.8% 35.4%
Living donor 35.7% 44.9%
Related 14.3% 17.2% 0.853
Unrelated 21.4% 27.8%
Atherosclerosis (macroscopic) 0.208
None/mild 76.0% 79.0%
Moderate 11.5% 14.1%
Severe 12.5% 6.8%
Cold ischemia time, h
Postmortal donor 13.8 ± 4.7 14.5 ± 4.5 0.360
Living donor 2.6 ± 0.5 2.7 ± 0.6 0.190
Second warm ischemia time, min 37 ± 10 37 ± 12 0.267
Perioperative complications 6.1% 7.1% 0.988
All results as percentages, mean ± standard deviation or median + interquartile range.
BMI, body mass index; ADPKD, autosomal dominant polycystic kidney disease; FSGS, focal segmental glomerulosclerosis; CMV, cytomegalovirus EBV, epstein-barr virus; DBD, donation after brain death; DCD,
donation after cardiac death.
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FIGURE 3. Tacrolimus trough levels.
© 2018 Wolters Kluwer van Sandwijk et al. 5higher in the early steroid withdrawal group (Figure 3). From
the third week onward, dosages were adequately adjusted so
that trough levels between the groups were indistinguishable.
Average mycophenolic acid dosages were not significantly
different for both groups: 930 mg daily in the early steroid
withdrawal group, compared to 994 mg daily in the standard
immunosuppression group (P = 0.123).
Primary Endpoint
There were no statistically significant differences in kidney
function between the 2 groups. This was true for MDRD,
creatinine clearance, and proteinuria (Table 2), both for the
intention-to-treat and the as-treated analysis. Sensitivity
analyses were performed with and without imputations for
graft failure, without significant changes in outcome.
Secondary Endpoints
Four patients died during the first 6 months of the ALLE-
GRO trial, 1 (1.0%) in the early steroid withdrawal group
and 3 (1.5%) patients in standard immunosuppression group.
The cause of death of the patient in the early steroid with-
drawal group was pneumosepsis; in the standard immuno-
suppression group, the causes of death were pneumosepsis
and 2 cases of sudden death at home. Primary nonfunction
occurred in 4.1% of patients in the early steroid withdrawal
group and in 1.5% of patients in the standard immunosup-
pression group, whereas graft failure occurred in 3.1% andTABLE 2.
Primary endpoint (kidney function)
Early steroid withdrawal
Intention-to-treat 98 patients
eGFR (MDRD, mL/min per 1.73 m2) 43.2 ± 18.0
Creatinine clearance, mL/min 58.5 ± 24.4
Proteinuria, g/24 h 0.20 [0.12-0.31]
As-treated 53 patients
eGFR (MDRD, mL/min per 1.73 m2) 50.5 ± 13.9
Creatinine clearance, mL/min 67.1 ± 24.2
Proteinuria, g/24 h 0.19 [0.12-0.27]
In case of graft failure, an eGFR of 10 mL/min per 1.73 m2 and creatinine clearance of 10 mL/min were imp
in significant changes in outcome.1.5% of patients, respectively. The combined rate of death,
primary nonfunction, and graft failure was not significantly
different between the 2 groups (P = 0.325, Figure 4A). Rejection
(Table 3) occurred in 18.6% of patients in the early steroid
withdrawal group compared with 13.6% in the standard
immunosuppression group (P = 0.289, Figure 4B). There
was no statistically significant difference in steroid-resistant
rejections (P = 0.564). In the early steroid withdrawal group,
19.6% of patients had to discontinue their study medication,
compared with 12.6% in the standard immunosuppression
group (P = 0.164, Figure 4C). The reasons for the discontinu-
ation of study medication were varied (see Table 4) and in-
cluded infectious complications (4.1% in both groups),
mycophenolic acid toxicity (3.1% in the early steroid with-
drawal group vs 1.0% in the standard immunosuppression
group, P = 0.382), and a requirement for prednisolone for
reasons other than rejection (in 4.1% of patients in the early
steroid withdrawal group, eg, due to interstitial nephritis or
hyponatremia). Treatment failure, defined as the composite
endpoint of death, primary nonfunction, graft failure, rejection,
and interruption of study medication for more than 6 weeks,
occurred more frequently in the early steroid withdrawal
group (P = 0.024, Figure 4D).
Serious adverse events were less common in the early ste-
roid withdrawal group (44.3 vs 56.6 per 100 patients,
P = 0.048, Table 5), which was mostly attributable to a lower
rate of infections. The early steroid withdrawal group alsoStandard immunosuppression P
199 patients
45.0 ± 16.1 0.408
58.3 ± 28.6 0.949
0.19 [0.11-0.30] 0.771
133 patients
47.2 ± 15.4 0.175
61.5 ± 21.7 0.137
0.18 [0.11-0.30] 0.910
uted. Sensitivity analyses were performed with and without imputation of these values and did not result
FIGURE 4. Percentage of patients free from (A) death, primary nonfunction, and graft failure, (B) rejection, (C) interruption of study medication,
and (D) any type of treatment failure.
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(Table 6): an improved diastolic blood pressure, and a
lower total cholesterol and LDL, despite a lower percentage
of patients on cholesterol lowering agents in the early
steroid withdrawal group (32% vs 37.9%). The percentage
of patients with new onset diabetes mellitus type II, defined
as initiation of oral hypoglycemic agents or insulin for at
least 30 consecutive days, was higher in the standardTABLE 3.
Rejections
Early steroid
withdrawal
Standard
immunosuppression P
Treated rejections 18.6% 13.6% 0.289
Acute AMR 7.2% 4.0% 0.266
Acute TCMR 0.128
Grade IA 2.1% 1.0%
Grade IB 1.0% 0%
Grade IIA 5.2% 3.0%
Grade IIB 3.1% 1.5%
Grade III 0.0% 0.5%
Borderline acute TCMR 3.1% 2.5% 0.805
Inadequate biopsy but
treated as rejectiona
0% 2.5% 0.058
Rejections graded according to Banff 2015 criteria8.
a Biopsies with less than seven glomeruli.
AMR, antibody-mediated rejection; TCMR, T cell–mediated rejection.immunosuppression group (34.7% vs 24.3%), but due to a
baseline difference in diabetes mellitus type 2 prevalence in
both groups (24.2% in the standard immunosuppression
group vs 14.4% in the early steroid withdrawal group), the
increase was not statistically significant.
Subgroup analysis for different donor types
No differences in MDRD were found for different donor
subtypes, but living donor kidney recipients had a higher cre-
atinine clearance (64 mL/min) and a lower median protein-
uria (0.16 g/d) compared to DBD (53 mL/min; 0.19 g/d;TABLE 4.
Reasons for Discontinuation of study medication
Early steroid
withdrawal
Standard
immunosuppression P
Infectious complications 4.1% 4.1% 0.481
Tacrolimus toxicity 4.1% 2.5% 0.860
Inability to maintain adequate
tacrolimus levels
2.1% 3.5% 0.179
MMF toxicity 3.1% 1.0% 0.382
Requirement for prednisolone for
reasons other than rejectiona
4.1% 0.0% 0.013
Other 2.1% 1.5% 0.929
a Initiation of prednisolone after a rejection in the early steroid withdrawal group was standard practice
in the ALLEGRO trial and was therefore not included in this endpoint.
TABLE 5.
SAEs per 100 patients
Early steroid
withdrawal
Standard
immunosuppression P
SAEs 44.3 56.6 0.048
Urinary tract infections 11.3 12.1
Other infections 7.2 16.2
Cardiovascular event 3.1 2.5
Gastrointestinal event 7.2 6.1
Malignancy 0.0 1.5
Urologic event 2.1 3.5
Vascular event 0.0 2.5
Psychiatric event 3.1 1.0
Pulmonary event 2.1 2.0
Other 7.2 7.1
© 2018 Wolters Kluwer van Sandwijk et al. 7P = 0.012) and DCD recipients (55 mL/min; 0.20 g/d;
P = 0.047). These trends were the same for both the early ste-
roid withdrawal and the standard immunosuppression
group. Three of 4 deaths occurred in the DCD group and 1
in a living donor kidney recipient (P = 0.242). No significant
differences in primary nonfunction and graft failure were
found for different donor types, but there was a trend of a
lower rejection rate in the DBD group (8%versus 19% in liv-
ing donor kidney transplant recipients and versus 16% in
DCD recipients, P = 0.117). For all donor types, there were
no significant differences in the above outcomes between
the early steroid withdrawal and the standard immunosup-
pression group.
DISCUSSION
These interim results of the ALLEGRO trial show that
early steroid withdrawal in living donor, DBD, and DCD
kidney transplant recipients is noninferior compared with
standardmaintenance immunosuppressionwith basiliximab,
tacrolimus, mycophenolic acid, and corticosteroids in terms
of kidney function at 6 months. Early steroid withdrawal
has been evaluated in 2 recent meta-analyses,9,10 but the tri-
als included in these meta-analyses were very heterogeneous
in terms of timing of steroid withdrawal and concurrent immu-
nosuppression. Only 4 trials are directly comparable to the AL-
LEGRO trial.11-14 These trials are summarized in Table 7 and
confirm the noninferiority of early steroid withdrawal in terms
of kidney function. What our analysis adds to these resultsTABLE 6.
Cardiovascular risk factors
Early steroid withdrawal
Blood pressure, mm Hg 141/84→ 138/79
% of patients with diabetes mellitus 14.4%→ 24.7%
HbA1C, mmol/mol 39.4→ 42.9
Total cholesterol, mmol/L 4.6→ 4.8
HDL, mmol/L 1.3→ 1.3
LDL, mmol/L 2.4→ 2.7
Triglycerides, mmol/L 2.2→ 2.0
% of patients on cholesterol lowering agent 32.0%
a P values for systolic and diastolic blood pressure.
HDL, high-density lipoprotein; LDL, low-density lipoprotein.is that early steroid withdrawal is also noninferior in terms
of proteinuria, an important predictor of graft survival.15
We are also the first study to have included recipients of living
donor, DBD, and DCD kidneys with a low to intermediate
immunological risk.
In our study, early steroid withdrawal did not increase the
6-month incidence of the individual secondary endpoints of
death, primary nonfunction, and graft failure. We did find a
somewhat higher rate of rejection in the early steroid with-
drawal group (18.6% vs 13.6%), but this difference was not
statistically significant. This contrasts with the study byWoodle
et al,13 who found a significantly higher rate of biopsy-proven
rejection in the steroid withdrawal group (17.8% vs 10.8%),
despite using either thymoglobulin, daclizumab, or basiliximab
according to local center preference, whereas we used
basiliximab in all cases. However, our study could be under-
powered to detect differences in the rate of rejection.
Although rejection rates and patient and graft survivals
were comparable in both groups, the early steroid withdrawal
group was at increased risk for the composite endpoint of
treatment failure. This was largely due to a higher percentage
of discontinuation of study medication, for example, because
of mycophenolic acid toxicity or a requirement for predniso-
lone for reasons other than rejection. The relatively high rate
of discontinuation of study medication also explains the rela-
tively small number of patients in our as-treated analysis,
which is one of the limitations of our study. Other limitations
include a relatively short follow-up duration and a heteroge-
neous (but real-life) study population. Lastly, the ALLEGRO
study is not double-blind, but we believe that any bias would
be limited, because tacrolimus levels were very comparable
in both groups. The reported difference in tacrolimus levels
in week 2 was most likely due to an interaction of predniso-
lone with tacrolimus, resulting in lower tacrolimus trough
levels in the standard immunosuppression group. This phenom-
enon has been described previously16 and was confirmed by an
analysis of average Advagraf dosages, which were slightly
higher in the standard immunosuppression group (13.5 mg vs
12.7mg once daily) despite lower trough levels in that group.
Based on these interim results, we believe that steroid-free
maintenance immunosuppression is a safe short-term strat-
egy for living donor, DBD and DCD kidney transplant recip-
ients with a low to intermediate immunological risk.
Although associated with an increased risk of treatment fail-
ure, it does not impair kidney function at 6months, as well as
having the benefits of a decreased risk of infections and anStandard immunosuppression P
141/81→ 138/80 0.303/0.030a
19.7%→ 34.3% 0.310
39.1→ 45.1 0.811
4.5→ 5.5 0.005
1.2→ 1.5 0.010
2.3→ 3.0 0.106
2.3→ 2.3 0.675
37.9%
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8 Transplantation DIRECT ■ 2018 www.transplantationdirect.comimproved cardiovascular risk profile. Whether this will out-
weigh possible long-term risks, such as the possibility of in-
creased donor-specific antibody formation or increased
calcineurin inhibitor toxicity compared to the tacrolimus
minimization group, will be addressed in our definitive
2-year analysis.
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